Sangamo BioSciences, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 105

Sangamo BioSciences, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Sangamo BioSciences, Inc. - Product Pipeline Review - H2 2011” provides data on the Sangamo BioSciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sangamo BioSciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sangamo BioSciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sangamo BioSciences, Inc. - Brief Sangamo BioSciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sangamo BioSciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sangamo BioSciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sangamo BioSciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sangamo BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sangamo BioSciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sangamo BioSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sangamo BioSciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sangamo BioSciences, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Sangamo BioSciences, Inc.; Sangamo BioSciences, Inc. - Key Therapeutics; Sangamo BioSciences, Inc. - Pipeline Overview and Promising Molecules; Sangamo BioSciences, Inc. - News; Sangamo BioSciences, Inc. - Latest Updates; Sangamo BioSciences, Inc. - Pipeline; Sangamo BioSciences, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Sangamo BioSciences, Inc. Snapshot
Sangamo BioSciences, Inc. Overview
Key Information
Key Facts
Sangamo BioSciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Sangamo BioSciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Sangamo BioSciences, Inc. – Pipeline Products Glance
Sangamo BioSciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sangamo BioSciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sangamo BioSciences, Inc. – Drug Profiles
SB-313
Product Description
Mechanism of Action
R&D Progress
SB-728-T
Product Description
Mechanism of Action
R&D Progress
ZFN For Monogenic Diseases
Product Description
Mechanism of Action
R&D Progress
ZFP TF for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
ZFP TFs For Nerve Regeneration
Product Description
Mechanism of Action
R&D Progress
Sangamo BioSciences, Inc. – Pipeline Analysis
Sangamo BioSciences, Inc. – Pipeline Products by Therapeutic Class
Sangamo BioSciences, Inc. - Pipeline Products By Target
Sangamo BioSciences, Inc. – Pipeline Products by Route of Administration
Sangamo BioSciences, Inc. – Pipeline Products by Molecule Type
Sangamo BioSciences, Inc. – Recent Pipeline Updates
Sangamo BioSciences, Inc. - Dormant Projects
Sangamo BioSciences, Inc. – Company Statement
Sangamo BioSciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 30, 2005: Sangamo BioSciences Completes Enrollment And Treatment In Phase 1 Clinical Trial Of ZFP Therapeutic SB-509 In Diabetic Neuropathy
Aug 30, 2004: Edwards Lifesciences Initiates Phase II Clinical Trial Of EW-A-401
Nov 29, 2006: Sangamo BioSciences Initiates Phase 2 Clinical Trial Of Novel Therapy SB-509 For Diabetic Neuropathy
Jun 29, 2010: Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data At ADA 2009
Jun 29, 2010: Sangamo BioSciences Presents Positive Phase II ZFP Therapeutic Data From SB-509 Programs In Diabetic Neuropathy At ADA 2010
Feb 28, 2011: Sangamo Announces Presentation Of Positive Clinical Data From New ZFN Therapeutic Approach For Treatment Of HIV/AIDS
Oct 26, 2006: Sangamo BioSciences And JDRF Announce Partnership For ZFP Therapeutic SB-509 For Diabetic Neuropathy Program
Jun 26, 2007: Sangamo BioSciences Initiates Additional Phase 2 Clinical Trial Of SB-509 For Moderate To Severe Diabetic Neuropathy
May 26, 2006: Sangamo BioSciences'Announces Publication Of Diabetic Neuropathy Program (SB-509) In The Journal Of American Diabetes Association
Apr 26, 2007: Sangamo BioSciences Initiates Additional Phase 2 Clinical Trial Of SB-509 In Diabetic Subjects With 'Blocked Nerves'
Sep 23, 2009: Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Jun 23, 2005: Edwards Lifesciences Announces To initiate Phase I Clinical Trial Of EW-A-401
Jun 22, 2007: Sangamo BioSciences Announces Presentation Of Phase 1 ZFP Therapeutic (SB-509) Data At American Diabetes Association Meeting
Oct 20, 2009: Sangamo BioSciences Announces Presentation Of Top-Line Statistically Significant Phase 2 SB-509 Data In Diabetic Neuropathy At Society For Neuroscience Meeting
Nov 18, 2009: Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Sep 18, 2011: Sangamo BioSciences Announces Presentation Of New Clinical Data From ZFN Therapeutic For HIV/AIDS At ICAAC 2011
Sep 18, 2006: Sangamo BioSciences Announces Presentation Of ZFP Therapeutic SB-509 Clinical Data From Diabetic Neuropathy Program At Major European Diabetes Meeting
Nov 17, 2010: Sangamo BioSciences Announces Presentation Of Phase II Data In Amyotrophic Lateral Sclerosis At Society For Neuroscience Meeting
Sep 15, 2008: Sangamo BioSciences Announces Presentation Of Data From Diabetic Neuropathy Clinical Trials Of SB-509
Dec 13, 2010: Sangamo Announces Publication Of Data From Program To Develop ZFP Therapeutic For Parkinson's Disease In Journal Of Neuroscience.
Oct 13, 2011: Sangamo Announces Publication In Nature of Gene Correction Strategy For Alpha 1-Antitrypsin Deficiency
Jun 12, 2006: Sangamo BioSciences Announces 'Late-Breaking' Presentation Of Phase 1b ZFP Therapeutic SB-509 Data At American Diabetes Association Meeting
Jan 11, 2010: Sangamo BioSciences Announces Initiation Of Two New Clinical Trials Of ZFP Therapeutic For The Treatment Of Diabetic Neuropathy And Glioblastoma
Nov 10, 2008: Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Jan 10, 2011: Sangamo BioSciences Completes Enrollment In Phase IIb Diabetic Neuropathy Trial
Jan 10, 2005: Sangamo BioSciences Files Investigational New Drug Application For ZFP Therapeutic SB-509 To Treat Diabetic Neuropathy
Dec 09, 2009: Sangamo BioSciences Announces Phase 2 Study Results Of SB-509 At International ALS Symposium
Dec 09, 2009: Sangamo BioSciences Announces Presentation Of Preliminary Data From Phase 2 Study Of SB-509 At International ALS Symposium
Sep 08, 2011: Sangamo BioSciences To Present New SB-728-T HIV/AIDS Data At 51st ICAAC
Jun 08, 2009: Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data At ADA 2009
Jun 08, 2008: Sangamo BioSciences Announces Presentation Of Phase 1b ZFP Therapeutic SB-509 Data At American Diabetes Association Meeting
Jan 07, 2008: Sangamo BioSciences Initiates Phase 2 Clinical Trial Of ZFP Therapeutic SB-509 In Stem Cell Mobilization
Nov 06, 2007: Sangamo BioSciences Announces Presentation Of Phase 1b ZFP Therapeutic (SB-509) Data At Society For Neuroscience Meeting
Jun 06, 2008: Sangamo BioSciences Provides Update On Diabetic Neuropathy Clinical Program SB-509-701
May 05, 2005: Sangamo BioSciences Initiates Clinical Trial For Novel Therapy (SB-509) For Diabetic Neuropathy
Dec 04, 2007: Sangamo BioSciences Announces Completion Of Enrollment Of Phase 2 Clinical Trial Of ZFP Therapeutic SB-509 For Diabetic Neuropathy
Dec 04, 2006: Edwards' Angiogenesis Program To Be Acquired By Sangamo
Oct 03, 2011: Sangamo's Phase IIb Trial Of SB-509 In Diabetic Neuropathy Fails To Meet Key Study Endpoints
Sep 03, 2008: Sangamo BioSciences Initiates Phase 2 Clinical Trial Of SB-509 For Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Sep 03, 2008: Sangamo BioSciences Initiates Phase 2 Clinical Trial Of Treatment For Amyotrophic Lateral Sclerosis (ALS)
Feb 03, 2009: Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Financial Deals Landscape
Sangamo BioSciences, Inc., Deals Summary
Sangamo BioSciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Sangamo BioSciences Acquires Angiogenesis Program From Edwards Lifesciences
Partnerships
Sangamo BioSciences Enters Into Collaboration With CHDI Foundation
Sangamo BioSciences Enters Into An Agreement With Sigma-Aldrich
Sangamo BioSciences Expands Research Agreement With Pfizer
Sangamo BioSciences Expands Co-Development Agreement With LifeScan
Sangamo BioSciences Enteres Into Co-Developement Agreement Pfizer
Sangamo BioSciences Expands Co-Development Agreement With LifeScan
Sangamo BioSciences Enters Into Co-Development Agreement With LifeScan
Licensing Agreements
Sigma-Aldrich Expands Licensing Agreement With Sangamo BioSciences
Sangamo BioSciences Enters Into Licensing Agreement With Pfizer
Sangamo BioSciences And Sigma-Aldrich Sign An Agreement With Roche
Sangamo BioSciences Enters Into Licensing Agreement With Dow AgroSciences
Sangamo BioSciences Signs An Agreement With Open Monoclonal Technologies
Sangamo BioSciences Expands Research And Licensing Agreement With Genentech
Sangamo BioSciences Enters Into Research And Licensing Agreement With Genentech
Sangamo BioSciences Enters Into Licensing Agreement With City Of Hope
MaxCyte Enters Into Licensing Agreement With Sangamo BioSciences
Sangamo BioSciences Signs An Agreement With Dow AgroSciences
Isogenica Enters Into Licensing Agreement With Sangamo Biosciences
Equity Offering
Sangamo BioSciences Completes Public Offering Of Common Stock For $51.6 Million
Sangamo BioSciences Completes Public Offering Of $22 Million
Sangamo BioSciences Completes Private Placement Of $30 Million
Sangamo BioSciences Completes Public Offering Of $20.93 Million
Sangamo BioSciences Completes Private Placement Of $19.5 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Sangamo BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sangamo BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
Sangamo BioSciences, Inc. – Monotherapy Products in Pipeline, H2 2011
Sangamo BioSciences, Inc. - Phase II, H2 2011
Sangamo BioSciences, Inc. - Phase I, H2 2011
Sangamo BioSciences, Inc. - Pipeline By Therapeutic Class, H2 2011
Sangamo BioSciences, Inc. - Pipeline By Target, H2 2011
Sangamo BioSciences, Inc. – Pipeline By Route of Administration, H2 2011
Sangamo BioSciences, Inc. – Pipeline By Molecule Type, H2 2011
Sangamo BioSciences, Inc. – Recent Pipeline Updates, H2 2011
Sangamo BioSciences, Inc. - Dormant Developmental Projects, 2010
Sangamo BioSciences, Inc., Subsidiaries
Sangamo BioSciences, Inc., Deals Summary
Sangamo BioSciences Acquires Angiogenesis Program From Edwards Lifesciences
Sangamo BioSciences Enters Into Collaboration With CHDI Foundation
Sangamo BioSciences Enters Into An Agreement With Sigma-Aldrich
Sangamo BioSciences Expands Research Agreement With Pfizer
Sangamo BioSciences Expands Co-Development Agreement With LifeScan
Sangamo BioSciences Enteres Into Co-Developement Agreement Pfizer
Sangamo BioSciences Expands Co-Development Agreement With LifeScan
Sangamo BioSciences Enters Into Co-Development Agreement With LifeScan
Sigma-Aldrich Expands Licensing Agreement With Sangamo BioSciences
Sangamo BioSciences Enters Into Licensing Agreement With Pfizer
Sangamo BioSciences And Sigma-Aldrich Sign An Agreement With Roche
Sangamo BioSciences Enters Into Licensing Agreement With Dow AgroSciences
Sangamo BioSciences Signs An Agreement With Open Monoclonal Technologies
Sangamo BioSciences Expands Research And Licensing Agreement With Genentech
Sangamo BioSciences Enters Into Research And Licensing Agreement With Genentech
Sangamo BioSciences Enters Into Licensing Agreement With City Of Hope
MaxCyte Enters Into Licensing Agreement With Sangamo BioSciences
Sangamo BioSciences Signs An Agreement With Dow AgroSciences
Isogenica Enters Into Licensing Agreement With Sangamo Biosciences
Sangamo BioSciences Completes Public Offering Of Common Stock For $51.6 Million
Sangamo BioSciences Completes Public Offering Of $22 Million
Sangamo BioSciences Completes Private Placement Of $30 Million
Sangamo BioSciences Completes Public Offering Of $20.93 Million
Sangamo BioSciences Completes Private Placement Of $19.5 Million

List of Figures
Sangamo BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Sangamo BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
Sangamo BioSciences, Inc. – Monotherapy Products in Pipeline, H2 2011
Sangamo BioSciences, Inc. – Pipeline By Therapeutic Class, H2 2011
Sangamo BioSciences, Inc. - Pipeline By Target, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Cisco - A Tenuous Turnaround